Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138
Authors:
- Jort J. van der SchansJSJort J. van der Schans
- Ziyu WangZWZiyu Wang
- Jennemiek van ArkelJAJennemiek van Arkel
- Thijs van SchaikTSThijs van Schaik
- Afroditi KatsarouAKAfroditi Katsarou
- Ruud RuiterRRRuud Ruiter
- Thomas BaardemansTBThomas Baardemans
- Huipin YuanHYHuipin Yuan
- Joost de BruijnJBJoost de Bruijn
- Sonja ZweegmanSZSonja Zweegman
- Niels W.C.J. van de DonkNiels W.C.J. van de Donk
- Richard W.J. GroenRGRichard W.J. Groen
- 1 August 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (20) , 4219-4229
Abstract
Purpose: The success of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T cells illustrates the potential of this novel therapy for multiple myeloma. Nonetheless, broadening CAR T-cell therapy beyond BCMA requires inventive strategies as there are only a few multiple myeloma– or plasma cell–specific target antigens. We investigated the feasibility of achieving multiple myeloma specificity by dual-split CD38/CD138 CAR targeting, whereby the stimulatory and costimulatory signals for T-cell activation are split into two separate stimulatory (sCAR) and costimulatory CARs (cCAR). Experimental Design: Using various combinations of CD38 and CD138 sCARs and cCARs with different affinities, we generated several dual-split CAR T cells and analyzed them for multiple myeloma–specific effector functions in vitro. The best-functioning CAR T cells were tested in vivo in a murine xenograft model. Results: We found optimal designs of both CD38sCAR/CD138cCAR and CD138sCAR/CD38cCAR combinations, that effectively lysed multiple myeloma cells but spared single CD38- or CD138-positive healthy hematopoietic cells. While the CD38sCAR/CD138cCAR T cells achieved multiple myeloma–specific activity solely due to the low affinity of the CD38sCARs, the multiple myeloma–specific cytotoxicity, cytokine release, and proliferation of CD138sCAR/CD38cCAR T cells were established through a true combinatorial stimulatory and costimulatory effect. The most optimal combination comprised a low-affinity CD138sCAR combined with a high-affinity CD38cCAR. These CD138sCAR/CD38cCAR T cells also showed dual-antigen specific anti–multiple myeloma effects in vivo. Importantly, they were also effective against multiple myeloma cells from daratumumab pretreated patients with decreased CD38 expression levels. Conclusions: We demonstrate the possibility to specifically target multiple myeloma cells, even after CD38 targeted therapy, with carefully-designed dual-split CARs directed against CD38 and CD138.Keywords
All Related Versions
Funding Information
- KWF (12967)
- Stichting Kompass
This publication has 38 references indexed in Scilit:
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity OptimizationMolecular Therapy, 2017
- CD138 mediates selection of mature plasma cells by regulating their survivalBlood, 2017
- Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinomaCancer Immunology, Immunotherapy, 2016
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaBlood, 2016
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myelomaHaematologica, 2016
- Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In VivoCancer Immunology Research, 2013
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cellsNature Biotechnology, 2012
- Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary SignalingJournal of Clinical Immunology, 2012
- A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distributionBritish Journal of Haematology, 2004
- Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells.Proceedings of the National Academy of Sciences, 1995